Literature DB >> 1650962

Anti-granulocyte antibodies (C-ANCA, P-ANCA, GS-ANA) studied by confocal scanning laser fluorescence microscopy, ELISA, and chemiluminescence techniques.

T Skogh1, C Dahlgren, K Holmgren, E Peen, O Stendahl.   

Abstract

Fifty-nine patient sera with antibodies against human polymorphonuclear neutrophil granulocyte (PMN) antigens, as determined primarily by indirect immunofluorescence microscopy (IIF) screening, were further analysed by enzyme-linked immunosorbent assays (ELISA). The antibodies were primarily characterized by their immunomorphological staining patterns on ethanol-fixed PMN as judged by conventional IIF microscopy, i.e. anti-neutrophil cytoplasmic antibodies (ANCA) giving a pancytoplasmic granular staining pattern (C-ANCA) or a diffuse perinuclear cytoplasmic pattern (P-ANCA), or granulocyte-specific anti-nuclear antibodies (GS-ANA) producing a homogeneous or peripheral nuclear staining pattern. The three distinct patterns were confirmed by confocal scanning laser IIF microscopy. As antigen substrates in the ELISA tests we used an extract from azurophil PMN granules, myeloperoxidase (MPO), and lactoferrin. As expected, most (but not all) of the C-ANCA positive sera turned out positive in the alpha-ELISA assay. Both P-ANCA and GS-ANA positive sera had high frequencies of antibodies against MPO. Occasional P-ANCA positive sera contained antilactoferrin antibodies. Although P-ANCA and GS-ANA in general probably represent the same type of auto-antibodies, we regard it appropriate to make a distinction between the two patterns, until the existence of 'true' granulocyte-specific ANAs has been ruled out. All sera were analysed for their ability to activate PMN in vitro as judged by the generation of a chemiluminescence (CL) response. Sera containing C-ANCA, as well as sera containing P-ANCA or GS-ANA, showed high frequencies of positive CL tests using 'resting' isolated PMN. The reactions were diminished, but not always abolished, by heat-treatment of the sera.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650962     DOI: 10.1111/j.1365-3083.1991.tb01530.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis. A case-control study.

Authors:  J Aisenberg; J Wagreich; J Shim; S Almer; E Peen; T Heimann; I M Gelernt; A Greenstein; P Rubin; N Harpaz
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

2.  Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease.

Authors:  E Peen; S Almer; G Bodemar; B O Rydén; C Sjölin; K Tejle; T Skogh
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

3.  Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis.

Authors:  H Locht; T Skogh; A Wiik
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

4.  Anti-lactoferrin antibodies and other types of anti-neutrophil cytoplasmic antibodies (ANCA) in reactive arthritis and ankylosing spondylitis.

Authors:  H Locht; T Skogh; E Kihlström
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

5.  Leucocyte activation by anti-lactoferrin antibodies bound to vascular endothelium.

Authors:  E Peen; T Sundqvist; T Skogh
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

6.  IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis.

Authors:  C Sandin; P Eriksson; M Segelmark; T Skogh; A Kastbom
Journal:  Clin Exp Immunol       Date:  2016-02-25       Impact factor: 4.330

7.  Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus.

Authors:  Lina Wirestam; Hanna Schierbeck; Thomas Skogh; Iva Gunnarsson; Lars Ottosson; Helena Erlandsson-Harris; Jonas Wetterö; Christopher Sjöwall
Journal:  Arthritis Res Ther       Date:  2015-11-23       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.